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Diarrhea caused by Vibrio cholerae is known to give long-lasting protection against subsequent life-threat-
ening illness. The serum vibriocidal antibody response has been well studied and has been shown to correlate
with protection. However, this systemic antibody response may be a surrogate marker for mucosal immune
responses to key colonization factors of this organism, such as the toxin-coregulated pilus (TCP) and other
factors. Information regarding immune responses to TCP, particularly mucosal immune responses, is lacking,
particularly for patients infected with the El Tor biotype of V. cholerae O1 or V. cholerae O139 since highly
purified TcpA from these strains has not been available previously for use in immune assays. We studied the
immune responses to El Tor TcpA in cholera patients in Bangladesh. Patients had substantial and significant
increases in TcpA-specific antibody-secreting cells in the circulation on day 7 after the onset of illness, as well
as similar mucosal responses as determined by an alternate technique, the assay for antibody in lymphocyte
supernatant. Significant increases in antibodies to TcpA were also seen in sera and feces of patients on days
7 and 21 after the onset of infection. Overall, 93% of the patients showed a TcpA-specific response in at least
one of the specimens compared with the results obtained on day 2 and with healthy controls. These results
demonstrate that TcpA is immunogenic following natural V. cholerae infection and suggest that immune
responses to this antigen should be evaluated for potential protection against subsequent life-threatening
illness.
Diarrhea caused by Vibrio cholerae is known to give long-
lasting protection against subsequent life-threatening illness
(2, 3, 15). The serum vibriocidal antibody response has been
well studied and has been shown to be correlated with protec-
tion (8, 16, 17, 18). However, this systemic antibody response
may be a surrogate marker for mucosal immune responses to
key colonization factors of this organism, such as the toxin-
coregulated pilus (TCP). TCP is essential for V. cholerae col-
onization of the small intestine both in an infant mouse model
of cholera (28) and during human infection (11). The gene
encoding the major pilin subunit, TcpA, is located within a
larger genetic element termed the Vibrio pathogenicity island
or TCP/ACF element (7, 19). Although TcpA is expressed by
both classical and El Tor biotypes of V. cholerae O1, as well as
by V. cholerae O139, there is only 80% amino acid identity
between the TcpA proteins of the two biotypes of V. cholerae
O1 (12, 13, 28). TcpA of El Tor V. cholerae O1 and TcpA of V.
cholerae O139 are identical (25).
In previous studies of the immune responses to TcpA in
patients with V. cholerae infections the workers have examined
patients infected with the classical biotype of V. cholerae O1 or
have utilized classical TcpA to assess immune responses in
patients infected with El Tor V. cholerae O1 (9). Recent studies
in which the in vivo-induced antigen technology has been used
have shown that TcpA is expressed during human infection
with El Tor V. cholerae O1 and is immunogenic (10). Evidence
for immunogenicity of El Tor V. cholerae O1 TcpA has also
been obtained with convalescent-phase sera by utilizing par-
tially purified El Tor TcpA and a monoclonal antibody-based
sandwich assay (1).
Recently, recombinantly produced and purified El Tor TcpA
has become available (5), and we utilized this reagent to carry
out a detailed and comprehensive study of the mucosal and
systemic immune responses to this colonization antigen in
specimens obtained from patients with natural infections
caused by El Tor V. cholerae O1 and V. cholerae O139 in
Bangladesh.
(Preliminary results from this study were presented at the
XII Annual Meeting of the International Centers for Tropical
Disease Research, Bethesda, Md., May 2003.)
MATERIALS AND METHODS
Study group. Patients with acute watery diarrhea due to V. cholerae O1 or
O139 were recruited to the study (Table 1). These patients included both males
and females with cholera caused by the V. cholerae O1 Inaba (n  30) and Ogawa
(n  30) serotypes, as well as patients with V. cholerae O139 infections. Healthy
individuals in the same age range and with the same socioeconomic status but
* Corresponding author. Mailing address: Laboratory Sciences Di-
vision, ICDDR,B, Mohakhali, Dhaka 1212, Bangladesh. Phone: 8802
8811751 to 8802 8811760, ext. 2431. Fax: 8802 8823116 or 8802
8826050. E-mail: fqadri@icddrb.org.
4448
with no history of diarrhea during the previous 3 months were included as
controls.
Microbiologic work-up. Cholera was confirmed in patients with acute watery
diarrhea by stool culture, and the organisms recovered were differentiated sero-
logically as V. cholerae O1 Ogawa, O1 Inaba, or O139 (24). Stools of patients
were also tested for the presence of other enteric pathogens (including Salmo-
nella, Shigella, and Campylobacter spp.) by culture, for the presence of entero-
toxigenic Escherichia coli by PCR, and for the presence of ova and parasites by
direct microscopy, and the results were negative. Stools of healthy controls
included in the study were screened for these pathogens and were negative.
Sample collection and preparation. After microbiological confirmation of
cholera, venous blood and feces were collected from patients after they had been
rehydrated. This occurred on the second day of hospitalization and was consid-
ered to be approximately 2 days after the onset of diarrhea (day 2). Serum and
FIG. 1. TcpA-specific IgA responses in ALS assays for patients with cholera due to V. cholerae O1 Ogawa (O1/Og), O1 Inaba (O1/In), or O139.
The data points indicate individual values, and the bars indicate geometric means. Asterisks indicate statistically significant differences between
the day 2 responses and the day 7 responses (one asterisk, P  0.01 to 0.001; two asterisks, P  0.001). Statistically significant differences between
the responses of healthy controls and the responses of patients during convalescence are indicated by dots (one dot, P  0.01 to P  0.001; two
dots, P  0.001). mAB, milliabsorbance units; HC, healthy controls.
TABLE 1. Clinical features of study subjects







No. (%) infected with V. cholerae
strain No. (%) with blood group of:







01 Ogawa 01 Inaba 0139 A B AB O Median 25 centile,75 centile Severe Mild
Patients 90 25 (18, 35)a 41 (45) 49 (55) 30 (33.3) 30 (33.3) 30 (33.3) 19 (21) 22 (25) 10 (11) 39 (43) 17 8, 24 88 12
Healthy
controls
30 29 (24, 35) 16 (53) 14 (47) NAb NA NA 7 (23) 10 (33) 2 (7) 11 (37) NA NA NA
a Median (25 centile, 75 centile).
b NA, not applicable.
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fecal samples were also collected 5 and 19 days later, during convalescence (that
is, 7 and 21 days after onset of the disease, respectively). For control patients,
single blood and fecal samples were collected.
Peripheral blood mononuclear cells (PBMCs) were isolated from blood col-
lected in heparinized vials (Vacutainer system; Becton Dickinson, Rutherford,
N.J.) by gradient centrifugation with Ficoll-Isopaque (Pharmacia, Uppsala, Swe-
den). Plasma collected from the top of the Ficoll gradient was stored in aliquots
at 20°C. Sera separated from blood collected in vials that did not contain any
additive were divided into aliquots and stored at 20°C for antibody assays.
Fecal extracts were prepared by mixing stools (1 g of feces in 4 ml of buffer) with
phosphate-buffered saline containing EDTA (0.05 M), protease inhibitors, soy-
bean trypsin inhibitor (100 g/ml), and phenylmethylsulfonyl fluoride (10 mM)
(23). One milliliter of fecal extract was equivalent to 0.25 g of stool. Fecal
extracts were frozen in aliquots at 70°C.
For tests involving stored serum and fecal extracts, samples from all 90 patients
were available for enzyme-linked immunosorbent assays (ELISA). For studies in
which fresh PBMCs were used as the antibody in lymphocyte secretion (ALS)
and antibody-secreting cell (ASC) assays, samples were available from only 50
cholera patients (15 patients with V. cholerae O1 Ogawa, 20 patients with V.
cholerae O1 Inaba, and 15 patients with V. cholerae O139) and from only 24
cholera patients (10 patients with V. cholerae O1 Ogawa, 10 patients with V.
cholerae O1 Inaba, and 4 patients with V. cholerae O139), respectively. Similarly,
samples for all assays were not available from all control participants. The
specific number of samples analyzed in each assay is indicated below.
Preparation of V. cholerae antigens used for immunologic assays. TcpA was
overexpressed in E. coli BL21 with a histidine tag fused at the amino-terminal
end and was prepared as described previously (5). Lipopolysaccharides (LPS)
from V. cholerae O1 Ogawa (strain X25049) and O1 Inaba (strain 19479) were
purified as described previously (30). The major pilin subunit of the mannose-
sensitive hemagglutinin (MSHA) was purified from V. cholerae O1 and was
prepared by a method described previously (14); MSHA was a gift from Ann-
Mari Svennerholm, Goteborg University, Goteborg, Sweden.
Detection of ASC in the circulation. The ASC assay is a well-established proxy
for mucosal immune responses at the gut surface. Ficoll-separated PBMCs
recovered from patients on days 2 and 7 after the onset of diarrhea were assayed
for TcpA-specific ASC by the ELISPOT technique (6) by using modifications
described previously (20, 22). Individual wells of nitrocellulose bottom 96-well
plates (Millititer HA; Millipore Corp., Bedford, Mass.) were coated with 0.1 ml
of TcpA (5 g/ml) in 50 mM carbonate buffer (pH 9.6) and kept overnight at
room temperature. Cells secreting antibodies of the immunoglobulin A (IgA),
IgG, and IgM isotypes specific for bound TcpA were determined as described
previously (20, 22). A positive ASC response was defined as more than 10
ASC/107 PBMCs. TcpA-specific ASC responses were studied in 10 patients
infected with V. cholerae O1 Ogawa, 10 patients infected with V. cholerae O1
Inaba, and 20 healthy controls. Since the incidence of infection caused by V.
cholerae O139 was low during the course of the study, ASC responses to TcpA
were determined in only four patients with V. cholerae O139 infections.
ALS. An optimized procedure for an alternate measure of the mucosal im-
mune response to antigens, the ALS assay, has been described recently (4, 23).
Since this technique can be used with samples that were previously collected and
frozen, we used the ALS assay to compare TcpA-specific responses in patients
with V. cholerae O1 and O139 infections, including patients seen in a previous
study of O139 infection (23).
For the ALS assay, isolated PBMCs separated from patient samples collected
on days 2 and 7 were incubated in 24-well tissue culture plates at a concentration
of 1  107cells/ml in RPMI medium (with 10% fetal bovine serum, 1% glu-
tamine, 1% sodium pyruvate, 1% penicillin-streptomycin) at 37°C in 5% CO2 for
48 h by using sterile techniques. After incubation, the plates were centrifuged at
1,200  g for 10 min, and the supernatants were collected. A protease inhibitor
cocktail containing aprotinin (0.15 M), leupeptin (10 M), sodium azide (15
M), and 4-(aminoethyl)benzenesulfonyl fluoride (0.2 M) was added to each
supernatant (10 l/ml of supernatant), and the samples were frozen immediately
in aliquots at 70°C until they were assayed. The ALS assay was used to
determine TcpA-specific IgA antibody responses in an ELISA as described
below; the anti-TcpA response was measured in 15 patients with a V. cholerae O1
Ogawa infection, 20 patients with a V. cholerae O1 Inaba infection, and 15
patients with a V. cholerae O139 infection. Twenty healthy volunteers were also
tested by the ALS assay.
Detection of TcpA-specific antibodies in sera, feces, and lymphocyte superna-
tants by ELISA. Serum samples collected from patients at the acute stage of
infection (day 2) and at the convalescent stage of infection (day 7 and day 21
after onset) were tested against TcpA (coating concentration in 50 mM carbon-
ate buffer [pH 9.6], 1 g/ml) by an ELISA by using previously described proce-
dures (20). The ALS specimens were assayed undiluted, while serum samples
were tested at a 1:200 dilution. The optical densities were measured kinetically
at 450 nm for 5 min, and the results were expressed as the change in milliab-
sorbance units per minute (26). Fecal extracts were tested for antibody to TcpA
by an ELISA, and the results were expressed as the change in milliabsorbance
units per microgram of total IgA in the extract (26). A twofold or greater
increase in the ELISA results between day 2 and either day 7 or 21 was consid-
ered a positive response.
Detection of LPS- and MSHA-specific IgA responses in sera, fecal extracts,
and lymphocyte supernatants from V. cholerae O1 patients. Immune responses in
sera, fecal extracts, and lymphocyte supernatants obtained from patients infected
with V. cholerae O1 Inaba (n  20) and V. cholerae O1 Ogawa (n  15) to
homologous LPS, as well as MSHA, were also studied by utilizing procedures
described previously (20–23). ELISA plates were coated with LPS at a concen-
tration of 2.5 g/ml or with MSHA at a concentration of 1.0 g/ml.
Statistical analyses. The Wilcoxon signed rank test, the rank sum test, and the
Mann-Whitney U test were used where applicable for statistical analysis. Data
were expressed as medians and 25 and 75 centiles or as geometric means. A
two-sided P value of 0.05 was considered significant. Analyses were carried out
by using the SigmaStat statistical software (Jandel Scientific, San Rafael, Calif.).
RESULTS
Clinical features of the study subjects. Patients with cholera
most commonly presented with a short history of diarrhea
TABLE 2. TcpA-specific ASC responses in patients with cholera
Study subjects n
IgA IgM







































10 0.01 (0.01, 0.01) NA NA 100 (0.01, 275) 0.016 70 0.01 (0.01, 0.01) NA NA
Patients infected with
V. cholerae O139
4 0.01 (0.01, 0.01) NA NA 100 (70, 160) 0.029 100 0.01 (0.01, 0.01) NA NA
a Statistical significance (P  0.05) was determined by the Wilcoxon signed rank test.
b Response rate indicates a twofold or higher number of antigen-specific ASC at convalescence compared to the number at day 2.
c Median (25 centile, 75 centile).
d NA, not applicable.
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(symptoms for 24 h or less), and 88% had severe diarrhea as
determined by World Health Organization criteria (Table 1).
The median ages, gender distributions, and ABO blood group
distributions were similar for patients and controls.
TcpA-specific ASC responses in blood. Study subjects had
very low TcpA-specific ASC responses on day 2 (Table 2). The
TcpA-specific ASC responses of the IgA isotype were signifi-
cantly elevated by day 7 in all three groups of study subjects
(Table 2). Seven of 10 patients with a V. cholerae O1 Ogawa
infection showed a positive IgA ASC response at day 7 (P 
0.009), as did 7 of 10 subjects infected with V. cholerae O1
Inaba (P  0.016). All four patients infected with V. cholerae
O139 studied showed an increase in TcpA-specific ASC re-
sponses on day 7. ASC responses were also seen in the IgG and
IgM isotypes, and the frequencies and magnitudes of the re-
sponses were similar. The levels of ASC responses to TcpA
were negligible in all 20 healthy controls studied and similar to
those seen on day 2 in the study subjects (results not shown).
TcpA-specific IgA responses in the antibody in the lympho-
cyte supernatant assay (ALS assay). TcpA-specific IgA re-
sponses were also seen in the ALS assay in patients on day 7 of
illness compared with the responses in patients on day 2 or in
healthy controls (Fig. 1). Twelve of 15 patients with a V. chol-
erae O1 Ogawa infection, 12 of 20 patients with a V. cholerae
O1 Inaba infection, and 10 of 15 patients with a V. cholerae
O139 infection showed increases in the ALS response at day 7
compared to the response at day 2. The TcpA-specific levels in
the ALS assay were low on day 2 and comparable to those seen
in healthy controls (the difference was not significant).
TcpA-specific antibody responses in sera of patients with
cholera. All three groups of patients infected with V. cholerae
showed significant increases in serum IgA antibody responses
to TcpA on days 7 and 21 compared to the responses on day 2
(Table 3). Sixty-three percent of the patients with a V. cholerae
O1 Ogawa infection showed a significant increase in the level
of serum IgA antibody to TcpA at day 7, compared with 60%
of the patients infected with V. cholerae O1 Inaba and 73% of
the patients infected with V. cholerae O139. The serum IgA
antibody levels in 30 healthy controls were low and comparable
to those seen at day 2 in patients (median, 3.83 milliabsorbance
units/min; range, 2.33 to 5.33 milliabsorbance units/min).
TcpA-specific IgA responses in fecal extracts. Patients with
a V. cholerae infection showed significant increases in TcpA-
specific antibody in fecal extracts on days 7 and 21 compared
with the levels on day 2 (Table 3). Significant increases in the
TcpA-specific antibody level in fecal extracts were found in
83% of the patients infected with V. cholerae O1 Ogawa, com-
pared with 80% of the patients infected with V. cholerae O1
FIG. 2. Immunoblot assay to detect TcpA-specific IgA antibodies in
sera and fecal extracts. (A) Sera of patients infected with V. cholerae O1
Ogawa (lane 1), V. cholerae O1 Inaba (lane 2), and V. cholerae O139 (lane
3) and a healthy control (lane 4); (B) fecal extracts of patients infected
with V. cholerae O1 Ogawa (lane 1), V. cholerae O1 Inaba (lane 2), and V.
cholerae O139 (lane 3) and a healthy control (lane 4).
TABLE 2—Continued
IgM IgG
































10.0 (0.01, 210) 0.025 60 0.01 (0.01, 0.01)c NA NA 70.6 (10, 120)c 0.03 80
15 (0.01, 50) 0.031 60 0.01 (0.01, 0.01) NA NA 125 (0.01, 230) 0.016 70
90 (75,115) 0.029 100 0.01 (0.01, 0.01) NA NA 90 (50, 190) 0.029 100
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Inaba and 77% of the patients infected with V. cholerae O139.
Low levels of fecal antibodies specific for TcpA were found in
healthy controls, and the levels were comparable to those seen
on day 2 in infected patients (median, 0.10 milliabsorbance
unit/min/g of total IgA; range, 0.0 1 to 2 milliabsorbance
units/min/g of total IgA).
Immunoblot assays for immune responses to TcpA with
serum and fecal extracts. We utilized Western immunoblotting
to detect specific antibody responses to the 20.5-kDa purified
TcpA protein separated by polyacrylamide gel electrophoresis.
The convalescent-phase sera of V. cholerae patients collected
on day 7 or 21 following infection specifically recognized the
TcpA protein when Western blotting was used (see represen-
tative patient samples in Fig. 2A). Fecal extracts from these
patients also specifically detected TcpA protein when Western
blotting was used (see representative patient samples in Fig.
2B). Over 80% of the patients with a V. cholerae O1 or O139
infection had antibody in the serum and/or fecal extracts that
recognized TcpA by day 7 of infection, whereas none of these
patients had antibody to this protein on day 2. In 10 healthy
controls, neither sera nor fecal extracts recognized TcpA when
immunoblotting was used.
Comparison of immune responses to TcpA with immune
responses to LPS and MSHA. We compared immune re-
sponses to TcpA, LPS, and MSHA in patients infected with V.
cholerae (Table 4). The responder frequency rates for TcpA
and MSHA in all three assays were similar, whereas the re-
sponder frequency rates for LPS were slightly higher in ALS
and serum assays. Overall, 93% of the patients with a V. chol-
erae O1 infection showed an IgA immune response to TcpA in
one or more of the assays (ALS, serum antibody, and antibody
in fecal extract).
DISCUSSION
The results obtained here demonstrate that the 20.5-kDa
subunit of TCP (TcpA) is immunogenic in patients infected
with V. cholerae O1 El Tor and V. cholerae O139 in Bang-
ladesh. Previous studies have shown that individuals convalesc-
ing from cholera have strong immune responses to the B sub-
unit of cholera toxin and to the LPS of the infecting strain (24).
Patients with cholera also have immune responses, albeit
weaker, to another type IV pilus of V. cholerae, the 17.4-kDa
pilus subunit of the MSHA (22, 23). The immune responses to
the B subunit of cholera toxin, to LPS, and to MSHA, however,
have not been shown to correlate with protection against sub-
sequent infection with V. cholerae. The vibriocidal antibody
response has been shown previously to correlate with protec-
tion (8, 16, 17, 18). However, this serum complement-fixing
antibody is unlikely to be active at the mucosal surface, where
complement is lacking. Therefore, the vibriocidal antibody re-
sponse may be a surrogate marker of a protective mucosal
immune response to another antigen.
Previous studies in which patients with cholera were exam-
ined for immune responses to TcpA either have been per-
formed with North American volunteers challenged with the
classical biotype of V. cholerae O1 or have utilized classical
TcpA for immune assays with patients infected with El Tor V.
cholerae O1 (9); these studies have shown that there are low
rates of seroconversion. However, given that classical and El
Tor TcpA exhibit only 80% amino acid identity (12, 13, 28),
these previous studies may have underestimated the immune
responses to TcpA in patients infected with El Tor V. cholerae
O1. The recent availability of recombinantly produced and
purified El Tor TcpA (5) has provided a more suitable reagent
for assessing these immune responses. The results reported
here demonstrate that both systemic and mucosal immune
responses to TcpA occur in patients infected with El Tor V.
cholerae O1, as well as in patients infected with V. cholerae
O139, and that these responses are comparable in magnitude
and frequency to those seen with LPS and MSHA. This dispels
previous speculation that TcpA may not be sufficiently anti-
genic to engender an immune response or that repeated expo-
sure may be needed for an adequate response. The rate of
TABLE 3. TcpA-specific IgA antibody responses in sera and feces of patients with choleraa
Study subjects n
Serum


























30 4.0 (2.3, 6.3) NA 9.35 (3.3, 31.7) 0.001 60 5.48 (3.3, 11.7) 0.010
Patients infected with
V. cholerae O139
30 4.58 (3.3, 5.7) NA 15.67 (7, 77.6) 0.001 73 10.16 (7, 28.97) 0.001
a Serum anti-TcpA IgA responses are expressed in milliabsorbance units per minute. Stool anti-TcpA IgA responses are expressed in milliabsorbance units per minute
per microgram of total IgA.
b Statistical signifance (P  0.05) was determined by using the Wilcoxon signed rank test.
c A twofold or greater increase in the response at convalescence compared to day 2 samples was considered a significant increase.
d Median (25 centile, 75 centile).
e NA, not applicable.
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immune responses to TcpA demonstrated here, in fact, is sim-
ilar to that seen with other V. cholerae antigens studied. It is
not yet known, however, whether an immune response to TcpA
is protective.
In addition to the ASC assay, we also assessed mucosal
immune responses to TcpA with the ALS assay. We have
previously shown that the mucosal immune responses to LPS,
CtxB, and MSHA assessed by the ALS assay are comparable to
the responses seen with the ASC assay. One of the important
features of the ALS assay is that supernatants recovered from
circulating lymphocytes obtained on day 7 of infection can be
stored frozen on a long-term basis and then assayed at a future
time. We utilized this property specifically to assess mucosal
immune responses to TcpA in patients infected with V. chol-
erae O139, using samples from a previous study. The results
obtained were comparable to those obtained in the ALS and
ASC assays for the small number of patients studied acutely.
This suggests that supernatants of lymphocytes collected dur-
ing an outbreak can be recovered and frozen for study of
immune responses at a later time, particularly when mucosal
immune responses to a newly isolated antigen need to be
measured. Since positive results in the ASC or ALS assay
differentiate recent infection from past exposure to the patho-
gen in question, this approach allows measurement of an acute
immune response at a later time.
We have an ongoing study in Bangladesh of patients hospi-
talized with cholera and their household contacts (27). Some of
the household contacts develop symptomatic cholera, some are
asymptomatically colonized, and some are not infected. Frozen
supernatants from circulating lymphocytes obtained from ex-
posed household contacts in the various categories after expo-
sure to V. cholerae are currently being analyzed by the ALS
assay to see if a robust mucosal immune response to TcpA
after exposure might be responsible for mediating protective
immunity.
In conclusion, our study showed that patients infected with
El Tor V. cholerae O1 or O139 in Bangladesh mount substan-
tial mucosal and systemic immune responses to the coloniza-
tion antigen TcpA and that these responses are comparable in
magnitude and frequency to the responses to other V. cholerae
antigens tested to date. We are currently examining whether
immune responses to this key colonization factor may be in-
volved in protective immunity, both in household contacts ex-
posed to V. cholerae and in individuals vaccinated with a live,
oral, attenuated cholera vaccine.
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